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Abstract 
The advancement of cancer treatment is a major aim of modern science, according to the 
fact that this disease is responsible for 13% of all deaths worldwide (25% in Austria). 
Chemotherapy based on platinum complexes is a major part in the field of treatment of cancer. 
Its advent was in the 1960s when Barnett Rosenberg discovered the antitumour activity of 
cisplatin. Nowadays there are, besides cisplatin, two other platinum-based drugs in worldwide 
clinical usage: carboplatin and oxaliplatin. Because of the insufficient selectivity of these 
platinum(II) compounds to attack only cancer cells, patients suffer from a variety of severe 
side effects. 
As a result, research turned its focus to the synthesis of platinum(IV) compounds, due to 
their chemical inertness. These characteristics are expected to raise the possibility for an oral 
application and increased selectivity. Platinum(IV) compounds have to be activated via 
reduction to develop their activity against tumours and therefore act as prodrugs. During 
reduction, the axial ligands are released. Hence, these ligands are of particular interest for 
target-oriented synthesis, since the features of a drug, like uptake into the tissue, can be 
improved without abating anti-tumour activity. Another great opportunity is the coupling to 
bioactive molecules to extend the spectrum of efficacy. 
The synthesis of platinum(IV) compounds experienced a crucial advance through 
carboxylation with cyclic anhydrides. The resulting free carboxylic acid besides the 
coordinated carboxylate allows further derivatisation to yield amides and esters. It has to be 
mentioned that there are two functional groups available which can be of disadvantage for 
further reactions with carrier molecules. This diploma thesis presents the successful synthesis 
of asymmetric platinum(IV) complexes: carboxylation with succinic anhydride of (OC-6-43)-
dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV) had led to a 
monocarboxylation, whereas the second hydroxido group was sterically inhibited. 
Derivatisation of the carboxylic acid with methanol yielded the corresponding ester. 
Furthermore, platinum(IV) complex was transformed with a secondary amine to the 
corresponding amide for the first time. Currently, cytotoxicity studies in human tumour cell 
lines are being performed with three of the synthesised compounds. 
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Zusammenfassung 
Die Verbesserung der Behandlungsmethoden von Krebs ist ein wichtiges Ziel der heutigen 
Forschung, vor allem wenn man bedenkt, dass diese Krankheit für 13% aller Todesfälle 
weltweit verantwortlich ist (25% in Österreich). Eine der wichtigsten Behandlungsmethoden 
ist die Chemotherapie mit Platinverbindungen. Ihre Anfänge liegen in den 1960er Jahren 
begründet, als Barnett Rosenberg die Antitumoraktivität von Cisplatin entdeckte. Heutzutage 
sind, neben Cisplatin zwei weitere platinhältige Chemotherapeutika weltweit für die klinische 
Anwendung zugelassen: Carbo- und Oxaliplatin. Jedoch führt die unzureichende Selektivität 
dieser Platin(II) Verbindungen dazu, dass nicht nur Krebszellen angegriffen werden. In 
weiterer Folge führt dies beim Patienten zum Teil schweren Nebenwirkungen. 
Dieser Umstand führte zu einer Verlagerung der Forschung hin zu Platin(IV)-
Verbindungen, da diese eine erhöhte Inertheit aufweisen. Diese Eigenschaften könnten zu 
einer möglichen oralen Applizierbarkeit und gesteigerten Selektivität führen. Platin(IV)-
Verbindungen werden durch Reduktion in die aktive Platin(II) Spezies überführt und agieren 
daher als Prodrugs. Die axialen Liganden werden während der Reduktion freigesetzt und sind 
daher für eine zielgerichtete Synthese von Wirkstoffen von besonderem Interesse. Durch 
Variation dieser Liganden können gewisse Eigenschaften, wie z.B. die Aufnahme in das 
Gewebe, verbessert werden, ohne die Aktivität der Substanz zu verändern. Darüber hinaus 
eröffnet sich die Möglichkeit, das Wirkspektrum durch eine Kopplung mit bioaktiven 
Molekülen zu erweitern. 
Das Repertoire zur Synthese von Platin(IV)-Verbindungen wurde durch die Umsetzung 
mit zyklischen Anhydriden enorm erweitert. Bei dieser Reaktion wird eine freie 
Carboxylgruppe erzeugt, die weitere Derivatisierung mit Aminen oder Alkoholen ermöglicht. 
Es muss angemerkt werden, dass immer zwei funktionelle Gruppen erhalten werden. Dieser 
Umstand kann, vor allem beim Umsatz mit Trägermolekülen, zu einigen Nachteilen führen. 
Diese Diplomarbeit enthält die erfolgreiche Synthese asymmetrischer Platin(IV)-Komplexe. 
Die Asymmetrisierung erfolgt bei der Carboxylierung von (OC-6-43)-Dichlorido(N,N-
dimethylethan-1,2-diamin)dihydroxidoplatinum(IV) mit Bernsteinsäureanhydrid durch 
sterische Hinderung der zweiten Hydroxylgruppe. Die erhaltene freie Carboxylgruppe wird 
  Zusammenfassung VI 
weiter umgesetzt zum Methylester. Außerdem wurde erstmalig ein Platin(IV) Komplex mit 
einem sekundären Amin zum entsprechenden Amid umgesetzt. Derzeit werden in vitro 
Untersuchungen in humanen Tumorzelllinien durchgeführt an drei der synthetisierten 
Verbindungen. 
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Introduction   1 
1 Introduction 
1.1 A Short History of Cancer 
Cancer is a long-known disease and is not restricted to human beings. The first 
description of this disease was already found in ancient Egypt in a manuscript dates back as 
far as 1600 B.C. Additionally, fossilised malignant bone tumours (osteosarcoma) have been 
found in ancient human mummies. 
Hippocrates (460-370 B.C.) formed the term carcinos and carcinoma, the Greek word for 
crab, because the appearance of tumours, finger-like spreading veins, reminded him of crabs. 
The Greek term was then translated into the Latin word cancer by Celsus (28-50 B.C.). 
When scientists in the 18th century began to perform autopsies to identify the reason for a 
patient’s death, John Hunter (1728-1793) had born the idea of removing the tumour by 
surgery. Down to the present day surgery is often used in cancer treatment, furthermore other 
methods of treatment are deployed like radiation, immunotherapy or chemotherapy. [1] 
 
1.2 Facts about Cancer 
In 2004 about 13% of all deaths worldwide were accounted for cancer diseases. In low-
income countries, poor health care provokes, besides cardiovascular diseases and cancer, an 
especially high mortality because of infectious and parasitic diseases. In the industrialised 
countries, cancer is the main cause of death after cardiovascular diseases and its number is 
rising continuously. The increasing number is a result of the changes in living conditions of 
modern society (higher life expectancy, decreased mortality for example). The leading causes 
for cancer to emerge are, aside from the personal genetic factors, several external factors like 
ultraviolet and ionising radiation, infections of certain viruses (e.g. hepatitis B or human 
immunodeficiency virus (HIV)) and different chemical compounds people ingest in the course 
of a lifetime, such as tobacco smoke, aflatoxine or alcohol. By avoiding major risk factors like 
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tobacco and alcohol abuse, overweight and stress an estimated 30% of deaths caused by 
cancer could be prevented. 
 
 
Table 1: Worldwide death causes by sex, 2004 
 
 
 
Which kind of cancer appears more frequently depends, apart from the aforementioned 
factors, on the genders. Men are more often affected by lung, stomach and liver cancer, 
whereas women primarily suffer from breast cancer, stomach and lung cancer. 
Hence, there is a major interest to raise public awareness for preventing risk factors, to 
reduce deaths by early detection of malignant tumours and to improve the methods of 
treatment. [2] 
 
1.3 Formation of Cancer 
Cancer formation is every possible appearance of malignant tumours that can grow in 
every part of a human body. 
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By outside influences cells may experience DNA damage, but in the majority of cases the 
body repair system can inhibit genetic harm. When cell division takes place and the DNA 
damage is replicated, permanent alteration in the nucleotide sequence (= mutation) is the 
consequence. Typically, a cascade of mutations is required to produce a malignant cell and in 
further steps a tumour, generated by uncontrolled division and proliferation of the mutated 
cell. Tumour growth requires formation of new blood vessels to get nutrient supply, so-called 
angionesis, otherwise the size of a tumour is limited to approximately 106 cells. The most 
dangerous development is metastasis: the spread of invasive cancer cells through the blood 
stream or lymphatic system to other parts of the body to form new tumours, which makes it 
difficult to eliminate the cancer. 
 
Classification of different types of cancer results from the tissue of origin the cancer cell 
emanates. Due to the fact that cell division has to proceed, especially high proliferating tissue 
is endangered to form neoplasm, like lung and gastrointestinal tract tissue respectively. [3, 4] 
 
1.4 Treatment of Cancer 
The method of choice to tread cancer depends on several different factors, like nature of 
cancer, progression of the illness and its localisation. Furthermore, the general condition of 
the patient like nutrition stage, age and mental condition is crucial. 
 
Nowadays, there are five types of treatment available:  
• Surgical oncology 
• Radiation therapy 
• Hormone therapy 
• Immunotherapy 
• Chemotherapy 
These methods are often combined, at which surgery is the main step in removing 
tumours. 
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Surgical incision of tumours is the longest-established treatment and still plays a big role 
to handle primary as well as secondary tumours. Surgery is also used for palliation by 
advanced cancer. Good results can be attained for breast and bowel cancer, but a complete 
removal of the tumour or the target organ has to be assured. On the contrary, survival rates for 
pancreatic and gastric cancer are lower than 10% for patients treated in Europe. 
 
The success of radiation therapy significantly depends on the irradiated tissue, because 
the cells lose reproductive capacity and infrequently they die of apoptosis. For this reason, 
cells with fast cellular turnover like skin or nervous system tissue respond more rapidly to 
radiation. The challenge is to accurately detect the total dose and continuance to harm the 
tumour at the most with minimum effect on the healthy surrounding tissue. 
 
Hormones naturally produced in the body can interfere with the development of 
malignant tumours. Hormone therapy correspondingly stands for the inhibition of hormones 
of the afflicted target organ, which maintain the growth of cancer. However, the appliance is 
limited to few types, breast and prostate cancer for example, which are closely associated to 
the hormone balance. Often tumours are intrinsically resistant or will develop resistance 
during treatment, so it is considered to combine this strategy with chemotherapy. 
 
Immunotherapy is a new method to stimulate the immune system of the patient to affect 
an anti-tumour response. There are two types of immunotherapy: Immunisation of the patient 
with agents that directly affect the tumour growth (active immunotherapy) or medication with 
materials to stimulate the body’s own defences to fight malignant cells (passive 
immunotherapy). Immunotherapy is not yet fully developed. 
 
Chemotherapy is a treatment, where cytotoxic chemical compounds are deployed. 
Chemotherapy is the method of choice for unlocalised tumours with high tendency towards 
metastasis. Furthermore it is used pre or postsurgical to minimise tumour volume or for 
treatment of residual tumour cells. Additionally, it is useful to combine different 
chemotherapeutics, which attack at different points of the cell cycle to gain overall tumour 
response. However, the lack of selectivity often leads to multiple severe side effects.  
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Nowadays there is a large amount of chemotherapeutics in clinical usage that can be 
classified by their mode of action: 
• alkylating agents (e.g. melphalan, chlorambucil) 
• anti-tumour antibiotics (e.g. daunorubicin, mitomycin C) 
• anti-metabolites (e.g. methotrexate, 5-flurouracil) 
• topoisomerase inhibitors (e.g. topotecan, etoposide) 
• signal transduction inhibitors (e.g. resveratrol) 
• anti-microtubule agents (e.g. vincristine, paclitaxel) 
• hormone and hormone antagonists (e.g. tamoxifen) 
• anti-tumour metal complexes [5] 
 
The last group includes cisplatin, carboplatin and oxaliplatin; the only three platinum-
containing chemotherapeutics in worldwide clinical use. 
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2 Antitumour Platinum Compounds 
 
The history of cytotoxic platinum compounds starts in the 1960’s, when Barnett 
Rosenberg accidentally discovered the anti-tumour activity of certain platinum containing 
coordination compounds. Originally, he wanted to examine the effect of an electric field on 
the growth of Escherichia coli, and found that cell division stopped, whereas the bacteria still 
had a filamentous growth. This effect later was ascribed to platinum complexes, which were 
formed in the presence of ammonium chloride, sunlight and the supposedly inert platinum 
electrode. [6] Based upon these results he tested various group 10 transition-metal compounds 
with respect to their activity against cancer. [7] The most powerful compounds were cis-
[PtCl2(NH3)2] (cisplatin, DDP) (1) and cis-[PtCl4(NH3)2], whereas the analogous trans-
compounds showed no effect. [8-10] 
Soon, cisplatin was established in clinical routine and its success as anticancer drug is 
unbroken up to date. Ever since that time an enormous amount of platinum complexes have 
been synthesised and about 35 compounds have entered clinical trials, but the majority of 
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Figure 1: The only three platinum complexes in worldwide clinical usage: (1) cisplatin; (2) carboplatin and 
(3) oxaliplatin 
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these compounds were abandoned, because of their inactivity and/or toxicity. [11] Today, only 
three platinum(II) complexes are approved for worldwide application (cisplatin (1), 
carboplatin (2), oxaliplatin (3) (Figure 1)); another three complexes are only regionally 
approved (nedaplatin (4), lobaplatin (5), and heptaplatin (6) (Figure 2)) and currently a few 
are in clinical trials. 
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Figure 2: Platinum complexes in regionally limited clinical usage: (4) nedaplatin (Japan), (5) lopaplatin (China), 
and (6) heptaplatin (South Korea) 
 
The small number of compounds used in chemotherapy results from enormously strict 
requirements in trials for clinical approval. The drug has to have at least one advantage over 
currently applied chemotherapeutics, like advanced or more selective activity against cancer, 
reduced side effects or the possibility of easier application. [12] 
Despite original assumption, the annual volume of platinum compounds in chemotherapy 
currently amounts about 3 bn  worldwide. [13] 
 
2.1 Structure-Activity Relationships 
Approximately one in every 10 000 compounds gets approved, so the motivation to find a 
way to design drugs more efficiently was and still is very high. However, before starting to 
design a certain drug, it is important to understand the interaction between the drug and the 
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targeted cancer cell. Based upon the analysis by Cleare and Hoeschele the following 
“structure-activity relationships” were first indicated: [14, 15] 
The complex should have… 
• cis geometry, whereas compounds with trans geometry are inactive. 
• necessarily a pair of cis leaving groups, which is not sufficient. 
• no charge. 
• moderately bound leaving groups, given that labile leaving groups are toxic and 
firmly bound ones are inactive. 
• two amine groups, with at least one proton. 
 
The validation of these rules remained untouched for long, because all of the compounds 
that have entered clinical trials were consistent with them. Today, all of these theses that were 
thought to be essential for generating an active drug have been disproved. [16] Furthermore, 
the acceptation of these structure-activity criteria has shortened the focus on cisplatin 
analogues. This may cause the fact, that fewer Pt(IV)-complexes have been synthesised, 
although their anti-cancer effect has been known since Rosenberg. [17] 
Concluding, although structure-activity relationships are not sufficient to find active 
drugs, they are still important for understanding the mechanism of action and especially for 
categorising complexes into groups with analogous modes of action. 
 
2.2 Platinum(II) Compounds 
2.2.1 Cisplatin 
Cisplatin (1) is a long known compound and over the time, synthesis has experienced 
several improvements. The structure was first published as “Peyrone’s salt” in 1844 by 
Michele Peyrone. [18] The most common and successful synthesis was reported in 1970 by 
Dhara et al, which is based on the trans-effect of ligands. [19] 
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Cisplatin was one out of four complexes, which entered clinical trials after the discovery 
of Rosenberg and was found active. In April 1971, the complex was first tested in a patient in 
the USA and 7 years later it was approved as anticancer drug. [20] Intense clinical research 
showed a curative effect of cisplatin in small cell and non-small cell bronchial carcinoma, 
ovarian and testicular tumours, cervix carcinoma, advanced bladder carcinoma, melanoma, 
soft tissue sarcomas and carcinomas of the head and neck; especially testicular cancer can 
now be cured in over 90% of cases. 
Cisplatin is applied intravenously in a chloride-containing solution over a period of 0.5 to 
2 hours. Prehydration with a salt-containing fluid to minimise nephrotoxicity is fundamental. 
The nephrotoxicity’s aggressiveness nearly led to abandonment of the clinical trials. Usually, 
a maximum amount of up to 200 mg/m2 is administered for high-dose cisplatin. Besides 
nephrotoxicity, there are other severe side effects associated to it, like ototoxicity, neuropathy, 
nausea and myelosuppression. [21, 22] 
 
There is a variety of brand names for cisplatin-containing drugs, like Platinol® (Swiss, 
Austria), Cis-GRY® and Platinex®. 
 
2.2.1.1 Mode of Action 
For developing new and more effective platinum drugs, it is fundamental to understand 
how cisplatin and analogues interact with cells and for this reason a huge amount of 
publications exists that analyse and discuss this mode of action, although it is not fully 
understood yet. 
 
Cisplatin enters the bloodstream by intravenous administration and an immediate binding 
to proteins in the blood plasma up to 90% of the administered platinum drug takes place; 
specifically to thiol groups found in human serum albumin for example. [23, 24] 
The cellular uptake can occur mainly via two pathways, primarily by passive diffusion or 
actively by copper transporter protein Ctr1P. [25] Aquation of cisplatin leads to the activated 
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species (Figure 3); this process is enabled by the much lower intracellular chloride 
concentration (~ 4 mmol/L), compared to the extracellular chloride concentration of about 
100 mM. The result is a mixture of species; the distribution of these depends on the pH and 
chloride concentration. [26, 27] 
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Figure 3: Behavior of cisplatin in aqueous environment 
 
It was found that the monoaquated platinum species is the major contributor of binding to 
genomic DNA (gDNA) and therefore is the main initiator of anticancer activity. [28] Only 1% 
of the total cellular platinum reach DNA, the primary target, because of the enormous binding 
to other cellular components like membrane phospholipids, RNA and especially sulphur 
containing biomolecules (glutathione and metallothionein). The preferred DNA binding area 
of cisplatin is located at nucleophilic nitrogen atoms of the nucleobases, usually the N7 atom 
of guanine in the major groove. There is a variety of known DNA adducts, such as 60-65% 
1,2-d(GpG), 20-25% 1,2-d(ApG) and 5-10% 1,3-d(GpNpG) intrastrand cross-links that can be 
considered the main products. Of little importance are the interstrand cross-links and 
monoadducts. [29-31] 
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The consequence of the formation of these adducts is a change and distortion of the DNA 
conformation, like bending of the axis and unwinding of the double helix, which eliminates 
the possibility of replication and transcription and leads to apoptosis and necrosis. [32-36] 
 
2.2.1.2 Mechanism of Cisplatin Resistance 
It is generally accepted that on the way to the DNA the administered cisplatin in large 
parts is lost because of binding to a variety of proteins and cellular compounds. In addition, 
there are different mechanisms that lead to resistance, intrinsic (e.g. colon cancer) or acquired 
ones (e.g. ovarian cancer). Due to the multifactorial impacts details of the pathway are not yet 
entirely resolved despite intense research. 
 
There are two possible ways to anticipate apoptosis: (i) preventing the platinum 
compounds to build DNA adducts by deactivation and/or (ii) removing them by different 
repair mechanisms of the cell. The multitude of possibilities to deactivate cisplatin before 
interfering with DNA was described in brief before (see Chapter 2.2.1.1), so here focus will 
be the cellular repair systems. 
 
Nucleotide excision repair (NER) is thought to be the most important way of removing 
DNA adducts. The best described NER system is mediated by UvrABC endonuclease in 
Escherichia coli, moreover it is more sensitive to platinum adducts than others. After the 
damage recognition step an incision in DNA is made at a range of approximately 25-30 
nucleotides in length, this sector is removed and a polymerase reconstructs up the new DNA 
fragment. [37-39] 
 
Mismatch repair (MMR) is a system to correct different defects of DNA-synthesis, like 
mispaired nucleotides. Repeated ineffective repair triggers a process that ends in programmed 
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cell death (apoptosis). Therefore an enhanced cytotoxicity of DNA adducts is observed in 
MMR proficient cells in the case of cisplatin and opposed loss of MMR leads to greater 
tolerance of or resistance against platinum species, as monitored in ovarian cancer. This 
resistance mechanism applies only to platinum drugs that form similar DNA adducts as 
cisplatin. [40-43] 
 
HMG Proteins (high mobility group proteins) are a group of small proteins, which 
recognise distortion of the DNA-helix and specifically bind to these sites. They play a role in 
damage recognition for example and initialise systems like NER and MMR. HMG proteins 
detect platinum DNA adducts effectively and mask them so they will not be repaired. This 
eventually leads to apoptosis. The ambitions to identify such proteins that bind specifically to 
platinum adducts and understand their biochemical processes are naturally high. [44] 
 
Deepening the knowledge of acquired tolerances and resistances is essential for designing 
more effective drugs. The comprehensiveness of the topic is particularly challenging, so only 
some important mechanisms could be described at this point. [29-31, 33-34, 45-50] 
 
2.2.2 Carboplatin 
Carboplatin (2) is a cisplatin derivative with two chloride ligands being replaced with 
1,1-cyclobutane dicarboxylate. The chelating ligand has the effect of stabilisation and in 
further succession reduction of nephrotoxicity without abating anti-tumour activity. 
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Carboplatin was the result of intense research after the raise of cisplatin and had entered 
phase I clinical trials in the UK in 1980 and finally was approved for clinical usage in 1992. 
Compared to cisplatin, it is not deactivated by thiol groups in the blood stream, thereby a 
decrease of some side effects is achieved, only myelosuppression is higher and is hence the 
dose-limiting factor. 
The mode of action is analogous to cisplatin, so it responds to the same tumour species, 
although the needed therapeutic dose of carboplatin is approximately four times higher 
(200-400 mg/m2) to achieve the same effect. The clinical usage requires absence of chloride-
ions in solution to avoid exchange of the ligands. The administration is intravenous without 
prehydration, due to the reduced effect on the kidneys. A recovery of about 90% of the 
injected dose is found in the urine. [20-22, 51] 
 
Carboplatin is available as Carbosol® (Austria), Neocarbo® or Onkocarbo® (Germany); 
the first commercially used brand name was Paraplatin®. 
 
2.2.3 Oxaliplatin 
Synthesised by Kidani et al., oxaliplatin (3) is a third-generation derivative, with activity 
against some cisplatin-resistant tumours.[52] Oxaliplatin has an oxalato leaving group, and a 
non-leaving DACH ligand (= R,R-cyclohexane-1,2-diamine ligand). 
 
The first clinical phase I study took place in France, and currently oxaliplatin combined 
with 5-fluorouracil is approved worldwide for colon cancer treatment. The reason for the 
different fields of application is caused by the fact that loss of the mismatch repair system 
(see Chapter 2.2.1.2) do not lead to resistance against oxaliplatin, because of the formation of 
different DNA adducts as opposed to cisplatin. The limiting factor of dosage is the 
neurotoxicity, other side effects are myelosurpression, diarrhoea and mucosa inflammation, 
whereas often the toxicities are reversible after completion of treatment. 
There is no prehydratation necessary because of the absence of nephrotoxicity. The 
intravenous administration of 50 mg/m2 is carried out in a 5% solution of glucose, and similar 
to cisplatin, oxaliplatin is affine towards glutathione and other plasma compounds. [20-22, 53, 54] 
                                                 
51
 J. Lokich; N. Anderson; Ann. Onc. 1998, 13-21 
52
 Y. Kidani; M. Noji; T. Tashiro; Gann 1980, 71, 637-643 
53
 B. Stordal; N. Pavlakis; R. Davey; Cancer Treatm. Rev. 2007, 33, 347-357 
  Antitumour Platinum Compounds 14 
 
An observable structure-activity relationship could be identified between the three 
DACH-isomeres, in which the activity sequentially decreases: [55] 
trans-R,R-DACH > trans-S,S-DACH > cis-R,S-DACH 
 
Oxaliplatin is commercially available as Eloxatin® (Austria, Germany) or Croloxat® 
(Germany). 
 
2.2.4 Regionally Limited Platinum(II) Complexes 
In the course of time it became difficult to obtain new platinum(II) compounds with better 
performance against neoplasms, on account of this only three more complexes were 
regionally approved as anticancer agents: nedaplatin (4), lobaplatin (5), and heptaplatin (6) 
(Figure 2). [11, 56] 
 
In 1995 nedaplatin (4) was approved in Japan. Its characteristics are very similar to those 
of carboplatin, it shows the same side effects (e.g. myelosuppression) and a small affinity to 
plasma proteins. Nedaplatin is amongst others effective against small and non-small cell lung 
cancer, testicular tumours and cancer of the neck and head. [21] 
 
Although lobaplatin (5) was developed in Frankfurt (Germany), it is only clinically used 
in China. Lobaplatin, which exists as a mixture of two diastereomeres, is effective against 
ovarian, esophageal, head and neck or small cell lung cancer. [57] 
 
Heptaplatin (6) shows impact on some cisplatin-resistant cell lines and is approved in 
South Korea for treatment of gastric cancer. The major side effects at intravenous 
administration are hepatotoxiticy and myelosupression. [58, 59] 
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2.2.5 Other Representatives of Platinum(II) Compounds 
The intense research in the field of platinum(II) complexes produced an amount of 
derivatives that did not correspond with the structure-activity relationships, a few of these 
entered even clinical trials (Figure 4 and Figure 5): 
 
One of the intentions was to develop complexes, which are protected against the reaction 
with thiol groups and human cell repair mechanism through a sterically demanding ligand. 
Picoplatin (NX473) (7) provided the best results, especially in small lung cancer and currently 
is in clinical trials. [60 ,61] 
 
By now, also trans-platinum-compounds were found active in vivo and in vitro when a 
bulky planar ligand replaces the ammine groups, e.g. trans-[PtCl2(py)2] (8). 
JM 335 (9), a trans-platinum(IV)-compound, has even achieved better results than the cis-
analogue. [62, 63] 
 
Pt
Cl
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NH3
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Pt
N
Cl
Cl
N
Pt
NH3
+Cl
NH2
+
Cl
OH
OH
(8) (9)
 
 
Figure 4: Structure of (7) Picoplatin, (8) trans-[PtCl2(py)2] and (9) JM 335  
 
Another group of innovative anti-cancer drugs are multinuclear platinum compounds, 
with BBR 3464 (10) e.g. entering phase II studies. As they build “long distance” products with 
DNA, several cisplatin-resistant tumours showed response. [64, 65] 
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Figure 5: Structure of (10) BBR 3464 
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2.3 Platinum(IV) Compounds 
Although Rosenberg simultaneously found that [PtCl4(NH3)2] (= platinum(IV) 
compound) and cisplatin (= the platinum(II) analogue) have an antiproliferating potential on 
malignant tumours, platinum(IV) compounds have suffered from little attention. However, 
platinum(IV) compounds offer a variety of characteristics to take advantage of, especially 
their increased inertness and consequently reduced toxicity and possibility of oral 
administration. Moreover, their octahedral coordination enables more synthetic ways for 
designing drugs on purpose. 
 
2.3.1 Platinum(IV) Anticancer Complexes Entering Clinical Trials 
Up to date, four platinum(IV) compounds entered clinical trials (Figure 6). 
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Figure 6: Platinum(IV) compounds: (11) iproplatin, (12) tetraplatin, (13) satraplatin and (14) LA-12  
 
Iproplatin (CHIP, JM9) (11) is highly soluble and showed decreased toxicity, even so it 
was abandoned in phase III clinical trials, because of its decreased activity compared to 
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carboplatin. Recently, it was shown that iproplatin is not reduced, as expected, to cis-dichloro-
platinum(II) and therefore interacts differently with the target DNA than cisplatin. [17, 66] 
 
Tetraplatin (Ormaplatin) (12) was declined in phase I, although it affects a variety of 
tumour cells, especially several cisplatin-resistant ones. The reason for the abortion of the 
trials was the significant neurotoxicity. [17, 67] 
 
Satraplatin (JM216) (13), currently in clinical investigation, is the first platinum 
compound, that could be administered orally. The resulting DNA adducts are not detected by 
mismatch repair proteins and therefore available for cisplatin-resistant tumours. [68, 69] Due to 
the fact that in phase III SPARC trial the overall survival rate was not significantly improved, 
GPC-Biotech decided not to deposit the application for approval by the FDA (US Food and 
Drug Administration). [70] 
 
LA-12 (14), a satraplatin analogue with a very bulky adamantylamine ligand, has been found 
to be more active and in addition well-tolerated than cisplatin. 
One reason for the high activity to induce apoptosis, as found by Procháska et al, is the 
inhibition of gap-junctional intercellular communication (GJIP). [11, 71, 72] 
 
2.3.2 Mode of Action 
It is generally believed that the kinetically inert platinum(IV) compounds have to be 
activated by reduction, through loss of their axial ligands, to the active platinum(II) species 
(Figure 7). They act therefore as prodrugs. Only the activated compound will bind to the 
targeted DNA and induce apoptosis. Essential is in this context at which point of metabolism 
reduction takes place. Extra-cellular activation leads to loss of an amount of drug by binding 
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to sulphur containing proteins, as already seen for cisplatin and analogues. Therefore, it would 
be of advantage, if intra-cellular reduction happens so that immediate interaction with DNA 
can follow. Intra-cellular reduction implies a decrease of side effects and a smaller dosage of 
the administered drug. [11, 17, 73, 74, 75] 
 
 
 
Figure 7: Mode of Action of platinum(IV) compounds[11] 
 
However, it is not impossible that already the platinum(IV) species bind to blood-plasma 
proteins or even to DNA-bases. [76, 77, 78] 
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2.3.3 Structure-Activity Relationships 
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Figure 8: octahedral 
platinum(IV) complex 
 
 
In general, platinum(IV) compounds consist of two axial 
ligands (X) that get lost upon reduction, two equatorial leaving 
groups (Y) for binding to DNA and furthermore two am(m)ine 
containing non-leaving groups (Figure 8). 
Possible factors, like lipophilicity, reduction potential or 
cellular uptake, that influence the pharmacokinetics and activity 
of a drug, depend on the ligands and their position. 
 
Especially the axial ligands alter the reduction potential, 
following the order Cl > OAc > OH, whereas complexes with 
axial chlorido ligands are reduced most easily.  
Furthermore the size of the equatorial ligand influences the reduction rate, the bulkier the 
smaller the rate. When a drug is reduced easily the possibility of extra-cellular reduction is 
higher. [17, 73, 76, 79] 
 
The lipophilic character of an anti-tumour compound is important for drug uptake, in that 
the ability of a lipophilic drug to enter the cell is significantly higher. This factor is mostly 
affected by the chain length of the axial carboxylato groups. Furthermore, it could be shown 
that with increasing lipophilicity cytotoxicity also increased. [17, 80] 
 
The structure-activity relationships are a good guideline for rationally designing drugs 
with specific characteristics, in particular since platinum(IV) compounds have been found 
more active than their platinum(II) analogues. [81] 
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3 Synthesis of Platinum Complexes 
3.1 Synthesis of Platinum(II) Compounds 
After discovering the anticancer activity of cisplatin, the synthesis was optimised by 
utilising the trans-effect, given that otherwise a mixture of cis and trans isomers is the result. 
The starting material is almost always potassium tetrachloroplatinate for all cis platinum(II) 
compounds that were synthesised since Rosenberg’s discovery. 
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Figure 9: Preparation of cisplatin and the correspondent trans-complex 
 
The trans-effect is a kinetic phenomenon and appears especially in square planar 
coordination complexes, although this effect can also be observed in octahedral ones. In 
general, the trans-effect is referable to an electronegative or other labilising ligand that 
weakens the bond in trans position to it. The trans directing ligand normally shows a very 
strong binding and therefore is difficult to substitute, whereas the labialised ligand can be 
replaced easily.[82] 
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Due to the high demands on clinically used drugs a further step in synthesis of cisplatin 
was established to minimise side-products and especially the formation of the trans isomer. 
This step includes the exchange of the chlorido to iodido ligands, taking advantage of the 
increased trans-effect of iodide. [83] 
 
For synthesis of platinum(II) compounds with chelating ligands like ethane-1,2-diamine, 
the reaction directly takes place in aqueous solution without addition of iodido ligands. This 
can be explained by the single choice of binding in adjacent positions and therefore 
prevention of forming the trans isomer. [84] 
 
3.2 Synthesis of Platinum(IV) Compounds 
For a long time, the synthesis of platinum(IV) compounds was mainly limited to the 
oxidation of platinum(II) complexes. Further reactions were not performed according to the 
reduced reactivity and increased kinetic stability of platinum(IV) complexes. 
 
3.2.1 Oxidation of Platinum(II) Compounds 
Oxidation of platinum(II) compounds can take place basically via two ways (Figure 10): 
(i) with hydrogen peroxide in aqueous solution to yield two axial hydroxido groups (A) 
(ii) or with chlorine gas to obtain the tetrachloridoplatinum(IV) compound (B) 
In addition, the dihydroxidoplatinum(IV) compound can be converted to the tetrachlorido 
analogue under extreme conditions such as high temperature and addition of concentrated 
hydrochloric acid (C). [85, 86, 87] 
Nowadays, further derivatisation of the axial hydroxido ligands can occur because of their 
nucleophilic behaviour. Up to now, practicable reactions with tetrachloridoplatinum(IV) 
compounds are badly. 
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3.2.2 Carboxylation Reported in Literature 
Carboxylation with typical agents used in organic chemistry leads to lipophilic 
platinum(IV) compounds and is furthermore of particular interest for the combination with 
bioactive components, due to the fact that the axial ligands are released during activation of 
the prodrug. 
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Figure 10: Synthesis of platinum(IV) compounds 
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Recently, a variety of publications appeared that deal with the carboxylation of axial 
hydroxido ligands by using various anhydrides and acyl chlorides (Figure 10). [88] 
 
In 1995 Giandomenico et al. synthesised platinum(IV) carboxylates, carbonates and 
carbamates by carboxylation of the axial hydroxido groups with anhydrides, pyrocarbonates 
or isocyanates (D). This approach enables most notably the coupling with bioactive 
molecules. [89] 
Shortly after, Galanski et al. published the successful derivatisation of the hydroxido 
ligands with fatty acyl chlorides of moderate reactivity in the presence of pyridine to trap 
released hydrochloric acid. [90] 
 
Pt
ClNH3
+
NH3
+
Cl
O
O
O O
Cl Cl
O
OO
ClCl
O
(16)
 
 
Figure 11: Structure of ethacraplatin 
 
Dyson and colleagues used this method to prepare aryl platinum(IV) complexes (E) 
showing improved cellular drug uptake due to the increased lipophilicity. [91] Furthermore, a 
platinum compound with ethacrynic acid as axial ligand (ethacraplatin (16)) was synthesised 
by using this synthetic procedure. Ethacrynic acid is a glutathione-S-transferase (GST) 
inhibitor, playing a central role in the mechanism of resistance against cisplatin. The synthesis 
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of ethacraplatin was only possible without addition of an amine base. Activation of the 
prodrug leads to one equivalent cisplatin and two equivalents of ethacrynic acid. Ethacraplatin 
leads to a faster growth inhibition (after ~24 h) in different cancer cell lines compared to 
cisplatin (after ~72 h).  [92] 
 
Finally, the turnover with cyclic anhydrides afforded terminal uncoordinated carboxy 
groups (F) and therefore enables the accessebility for further reactions, which were first 
reported by Navarro-Ranninger et al.. [93] The optimisation of the reaction by changing the 
solvent from CH2Cl2 to DMF brought about increased yields and decreased reaction time, as 
shown by Keppler and co-workers. [94] 
 
3.2.3 Further Derivatisation of the Terminal Carboxylic Acid 
Straight forward, derivatisation of the uncoordinated free carboxylic group was first 
utilised by Lippard and colleagues. They coupled estrogen via an amide bond to the 
carboxylic acid. 
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Figure 12: Scheme of synthesis: linking estrogen to platinum(IV) complexes 
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The idea behind this strategy is based on the fact that estrogen sensitises ER(+) cells 
(estrogen receptor positive) to cisplatin. Estrogen causes overexpression of HMGB1 (high 
mobility group B1) and subsequently the HMBG1 protein protects cisplatin adducts from 
NER thereby increasing the efficiency of the drug. [95] 
 
Keppler et al. then created a generic scheme for derivatisation of the free carboxylic acid 
with primary amines and alcohols to yield amides and esters. However, they used the 
formerly known peptide-coupling reagents 1,1’-carbonyldiimidazole (CDI) for activation of 
the carboxylic group. Additionally, the formation of esters requires a catalytic amount of a 
strong base, in this case the corresponding sodium alcoxide of the applied alcohol, while the 
amine reacts without addition of a strong base. [94, 96, 97] (for mechanism aspects see chapter 
5.1.2) 
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Figure 13: Derivatisation of bis(carboxylato)platinum(IV) complexes 
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3.2.4 Recent Developments in the Synthesis of Platinum(IV) Complexes 
Developments in the field of platinum(IV) compounds are numerous and therefore only a 
selection of interesting approaches is shown. 
 
Minimising the loss of platinum(IV) drugs on the way to the targeted tumour is a 
particular aim and for this reason Lippard and co-workers coupled platinum(IV) complexes 
with water soluble single-walled carbon nanotubes (SWNTs). SWNTs function as effective 
transporting vehicles to get the drug into the cell. The synthesis was carried out by 
asymmetric oxidation of cisplatin with hydrogen peroxide in excess of ethanol to yield only 
one axial hydroxido ligand, whereas the second axial position is protected by an alkoxido 
ligand. Carboxylation of the free hydroxido ligand took place with succinic anhydride and 
further linkage by amide bonds to the SWNT surface. One SWNT incorporates an average of 
65 platinum(IV) centers. [98] 
 
In 2008, the same group expanded the system and coupled the platinum(IV) compounds 
with folate instead of the axial alkoxido protecting group. Folic acid acts as substrate of the 
folate receptor (α-FR) which was found to be overexpressed in a wide variety of tumours. 
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Figure 14: Targeted prodrug-delivery system 
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So a very selective agent was produced; the delivery system increased the uptake into the 
cell and ensured subsequent targeting of cancer cells by the folate ligand. [99] 
 
Furthermore, Lippard et al. synthesised some platinum(IV)-peptide complexes that show 
high affinity to the integrins ανβ3, ανβ5 and the membrane-spanning surface protein 
aminopeptidase N (APN or CD13). Integrins are involved in cell-cell and cell-matrix 
interactions as transmembrane-spanning receptors. Integrins ανβ3 and ανβ5 are overexpressed 
during tumour-induced angiogenesis of endothelial cells making them a possible target. The 
same applies to the aminopeptidase N. It was reported that, the tripeptide sequence RGD 
(Arg-Gly-Asp) and NGR (Asn-Gly-Arg) can be bound to these receptors effectively. 
Accordingly, a mixture of mono- and disubstituted peptide complexes with this tripeptide 
sequences was prepared and subsequently separated via HPLC. As a reference the tripeptide 
AGR (Ala-Gly-Arg) which is known to bind unspecifically was used. [100] 
 
3.3 Click Chemistry as Possible Source for Biologically Active Ligands 
All times scientists have been occupied with the quest for effective procedures to produce 
highly demanded, common natural materials. Regarding nature’s chemistry, an obvious 
preference for carbon-heteroatom bonds as opposed to carbon-carbon bonds can be observed. 
In 2001, Sharpless et al. characterised “Click Chemistry” as a strong approach to generate 
molecules by composing small and easily available building blocks via carbon-heteroatom 
bond forming reactions. A reaction has to display a set of criteria to be suitable for Click 
Chemistry, as well-defined by Sharpless: the process has to be “modular, wide in scope, high 
yielding, generate inoffensive by-products (removed without chromatography) and 
stereospecific, furthermore it should display simple reaction conditions, readily available 
starting materials and benign or easily removed solvents”. [101] 
 
There are several types of reactions which pass the “Click Chemistry Criteria”, whereas 
the spectrum ranges from non-aldol carbonyl chemistry, carbon-carbon multiple bonds 
addition, nucleophilic substitution reactions, especially ring opening chemistry, to 
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cycloadditions of unsaturated molecules. The last group includes the Huisgen 1,3-dipolar 
cycloaddition which is the most potent Click Chemistry reaction. [100, 102, 103] 
 
3.3.1 Huisgen 1,3-Dipolar Cycloaddition 
Huisgen cycloadditions are reactions with two unsaturated molecules to yield five-
membered heterocycles. The most powerful and popular of this family is the formation of 
1,2,3-triazoles made of azides and alkynes. 
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Figure 15: Huisgen-1,3-dipolar cycloadditions: (a) thermic conditions yield an approximate 1:1 ratio of anti 
and syn product; (b) copper(I)-catalysed Huisgen leads to the anti product. 
 
The formation of the 1,2,3-triazole can occur either thermic, though high temperature and 
long reaction times are required and the result is a mixture of regioisomers, or copper(I)-
catalysed, which offers increased reaction rate and regioselectivity (Figure 15). An enormous 
benefit is the stability of all reagents in water and in presence of atmospheric oxygen, which 
enables the reaction in water as a solvent. 
 
The Cu(I) catalysed alkyne-azide coupling shows the possibility of a variety of different 
conditions without loss of reactivity. Copper in the oxidation state I is relatively instable in 
the presence of oxygen. Although the reaction takes place when directly adding Cu(I) salts 
(normally CuI or CuBr in presence of a base), triazole formation via reduction of Cu(II) salts 
(CuSO4 reduced by ascorbic acid for example) or oxidation of metallic copper (nanosized 
Cu(0) activated by amine hydrochloride e.g.) is favoured. For reactions sensitive to redox-
systems, the possibility of ligand-assisted Cu(I) 1,3-cycloaddition exists. The ligand has the 
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task to stabilise the oxidation state, whereas the problem is to choose a ligand which is neither 
too labile to lose the stabilisation potential nor too strong so that the catalytic activity is 
lost. [103] 
 
LnCu [LnCu]2
+
R1 H
R1 H
CuLn
-H+
R1 CuLn-1
R2
N3
R1 CuLn-2
N
N+
N
R2
R1
CuLn-2
N
N
N
R2
R1
N
N
N R2
CuLn-2
R1
N
N
N R2
A
B
C
D
E
 
 
Figure 16: Catalytic cycle of Cu(I) assistant click chemistry  
 
 
It exist a proposed stepwise mechanism for click chemistry supported by copper being 
based on kinetic studies. The first step is the formation of a copper-acetylene π complex (A) 
and subsequent ligand dissociation yields the acetylide (B). Then the azide displaces a further 
ligand (C). Benefited of the complexation a metallocycle (D) can be built and afterwards a 
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transformation to the triazole (E) takes place. The final step is regeneration of the 
catalyst. [103 -105] 
The mechanism demonstrates that only terminal alkynes can react in this way, 
furthermore formation of the copper-acetylene π complex explains the high tolerance against 
a variety of functional groups. It has to be mentioned that on the contrary the thermal 
cycloaddition favours a concerted mechanism. 
 
Due to the toxicity and the potential explosiveness, azide chemistry was neglected for a 
long time and nowadays experiences a renaissance. This may be caused by the fact that 
1,2,3-triazole derivatives offer a diversity of biological activities, like HIV inhibition [106] or 
as antibacterial agents. [107] 
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4 Research Objective 
The objective of this diploma work was the development and characterisation of novel 
platinum(IV) complexes. The focus was on the synthesis of near derivatives of already 
investigated compounds to examine consequences in small variances in structure such as 
methyl groups at different positions. 
The synthesis included the oxidation of platinum(II) to trans-dihydroxido compounds, 
transformation of the resulting compounds with succinic anhydride to obtain uncoordinated, 
free carboxylic acids, which were further used for derivatisation with support of CDI to 
receive the corresponding amides and esters. 
Furthermore, the challenge was to produce 1,2,3-triazoles as ligands by performing the 
Huisgen 1,3-dipolar cycloaddition of platinum(IV) alkyne derivatives. Triazoles are 
interesting ligands for coupling with platinum(IV) complexes because of their reported 
biological activity. 
 
The structures of the resulting complexes could be verified by elemental analysis, ESI-
MS, one- and two-dimensional multinuclear NMR spectroscopy (1H, 13C, 195Pt) and IR 
spectroscopy. 
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5 Results and Discussion 
 
5.1 Synthesis 
The origin of this work was given by three platinum(II) compounds, all of which were 
synthesised via established synthetic routes described in chapter 3: 
• (SP-4-2)-Dichlorido(ethane-1,2-diamine)platinum(II) (18) 
• (SP-4-3)-Dichlorido(N,N-dimethylethane-1,2-diamine)platinum(II) (19) 
• (SP-4-2)/(SP-4-3)-Dichlorido(N,N’-dimethylethane-1,2-diamine)platinum(II) (20) 
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Figure 17: Platinum(II) compounds used as starting complexes 
 
The starting material was K2[PtCl4] that was stirred in an aqueous solution with 
corresponding diamines to gain the platinum(II) compounds, followed by oxidation with 30% 
H2O2. It has to be pointed out that there are great differences in the solubility of the obtained 
dihydroxido compounds in water. While the ethane-1,2-diamine derivative precipitated from 
the reaction mixture, the methylated compounds had to be isolated by removing the solvent. 
 
5.1.1 Carboxylation 
For carboxylation of the dihydroxido compounds, succinic anhydride was used as 
reported by Reithofer et al.. 
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Taking into consideration that methyl groups led to sterical hindrance of the hydroxido 
groups, various products could be achieved. Carboxylation of enPtCl2(OH)2 brought about 
only the dicarboxylated product, whereas N,N-dmenPtCl2(OH)2 exclusively became mono-
carboxylated (21). This result can be attributed to the axial position of the methyl group. A 
particular challenge was the N,N’-dimethylethane-1,2-diamine derivative, due to the fact of 
the present stereoisomeres. The ratio of the diastereomeres of 1:1.4 could be deduced from the 
1H NMR of the dihydroxidoplatinum(IV) complex (see chapter 5.2.4). After reaction with the 
anhydride a mixture of di- and monocarboxylated product could be isolated, unfortunately the 
stereoisomeres could not yet be separated. 
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The whole synthesis was carried out in DMF as a 
polar solvent and at 70 °C. During the reaction time of 
about 24 h, the starting suspension turned clear to 
indicate the end of the reaction. After removing the 
solvent, the residue was dissolved in acetone, filtrated 
and the product could be isolated by precipitating with 
diethylether. No changes in reaction time or condition 
comparing the three dihydroxido complexes could be 
observed. 
 
Figure 18: Monocarboxylated 
product. 
 
5.1.2 Formation of Amides 
For the formation of amides a nucleophilic attack of the carboxylic group was required. 
Better yields could be achieved by activating the carboxylic acid with CDI, a compound that 
is widely spread as a peptide coupling reagent and in organic synthesis. [108, 109] The splitting 
off of CO2 and imidazole shifted the reaction equilibrium to the formation of the imidazolide 
intermediate. This intermediate is easily attacked by primary amines for example. 
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Figure 19: Formation of an amide bond with primary amines. 
 
Due to the obviously lower reactivity of secondary amines another synthetic pathway for 
formation of the amide bond was chosen. Activation of the amine took place by treatment 
with CDI and subsequent reaction with methyliodide. The corresponding carbamoylimidazole 
suffered from significant inertness against nucleophilic attack, therefore a further step with 
methyliodide to gain the carbonylimidazolium salt was required. [110] The salt readily reacted 
with the platinum(IV) carboxylic acid under mild condition (stirring at 60°C) in the presence 
of a base. 
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Figure 20: Formation of an amide bond with secondary amines. 
 
This procedure was successfully applied to the synthesis of enPtCl2(C6H10NO3)2 with 
moderate yields. 
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5.1.3 Formation of the Ester 
Transformation of the imidazolide intermediate with an alcohol was aggravated because 
of its minor nucleophilicity, hence the alcohol had to be deprotonated. The method of choice 
was the preparation of an alkoxide solution with metallic sodium, whereas only a catalytic 
amount was required. This can be accounted to the formation of the sodium salt of imidazole 
that was in equilibrium with the alkoxide 
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Figure 21: Catalytic process of esterification with sodium alkoxide 
 
A disadvantage of this method of esterification is that alcohols with other functional 
groups could prefer side reactions, as obtained in the case of propargyl alcohol. The alkyne 
group of propargyl alcohol shows a tendency for polymerisation in the presence of a base or 
heat. Another previously published method making use of propargyl bromide and K2CO3 was 
also not successful. [111] 
 
5.1.4 Synthesis of a 1,2,3-Triazole Derivative 
The presence of platinum restricted the choise of different conditions for click chemistry. 
The fact that platinum(IV) could easily be reduced made it impossible to use methods that 
were carried out via reduction of Cu(II). Consequently the only two ways for performing this 
reaction with platinum(IV) complexes were on the one hand the thermal type or on the other 
hand based on ligand assisted Cu(I). 
 
The starting component enPtCl2(C7H8O3N)2 was prepared by Michael Reithofer and 
placed at the disposal. Phenyl azide was used as azide component and was prepared via 
standard literature procedures. [112] 
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The thermal dipolar cycloaddition was carried out in aqueous solution at 100°C, within an 
hour, the solution turned black. Neither substrate nor product could be isolated, consequently 
the presumption was that decomposition took place. [113] 
 
For reaction with ligand assisted copper(I) the first choice was TBTA 
(tris(triazolylmethyl)amine) as ligand. [114] Initially a copper-TBTA complex had to be 
prepared to stabilise the oxidation state I of copper. Therefore, CuCl2*2H2O was added to a 
solution of TBTA in CH2Cl2 and the mixture was refluxed for 3 h. The result was a green 
solid of the complex [Cu(Cl(TBTA))]Cl*1.5H2O. This complex subsequently was added to a 
solution of alkyne and azide in DMSO:H2O (2:1) and was stirred at rt for 24 h. Unfortunately, 
the reaction did not take place and the starting substances were isolated. 
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Figure 22: Conducted experiments of Click Chemistry 
 
Another method, that combined Cu(I)Br with sulphur containing ligands in water as a 
solvent was evaluated. In this case, the azide and alkyne were suspended in water and 5 mol% 
Cu(I)Br and 10 mol% of dimethylsulfide were added. After stirring for 4 h, a small amount of 
triazole (less than 5% yield) could be isolated. By increasing the reaction time to about 24 h, 
the yield could be raised noticeable (~ 50%). Compared to published reaction rates for organic 
substrates, times were in the range of 5 min to 2 h, which means an enormous decrease of the 
reaction rate for platinum complexes. [115] Additionally, due to the insolubility of the isolated 
crude product (only soluble in DMSO and DMF) further purification could not be realised. 
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The observed broad NMR-signals of the product allowed the presumption that possibly 
complexation of copper by the product took place. 
 
However, the preparation of the close analogue of enPtCl2(C7H8O3N)2 with propargyl 
alcohol was not successful because of the problem of polymerisation (see chapter 5.1.3). 
Nevertheless, 1,3 cycloaddition of propargyl alcohol with phenyl azide to yield the 
corresponding triazole as white crystals was successful. The free alcohol group could 
afterwards be coupled to enPtCl2(C4H5O4)2 trough an ester bond. Likewise, the obtained 
substance could not be purified. 
 
5.2 Characterisation 
The synthesised platinum complexes were characterised by elemental analysis, 
electrospray ionisation mass spectrometry (ESI MS), infrared spectroscopy (IR) and 
multinuclear NMR spectroscopy (1H, 13C, 195Pt). The spectroscopic data are discussed in the 
following sections. 
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5.2.1 Elemental Analysis 
All synthesised compounds were analysed for their percentage composition of the 
elements C, H and N. 
 
Table 2: Elemental analysis data of selected compounds 
Compound  C H N 
enPtCl2 Calculated 7.37 2.47 8.59 
 Found 7.46 2.36 8.47 
N,N-dmenPtCl2 Calculated 13.57 3.42 7.91 
 Found 13.40 3.05 7.92 
N,N’-dmenPtCl2 Calculated 13.57 3.42 7.91 
 Found 13.61 3.18 7.84 
enPtCl2(OH)2 Calculated 6.67 2.80 7.78 
 Found 6.41 2.51 7.42 
N,N-dmenPtCl2(OH)2 Calculated 12.38 3.64 7.22 
 Found 12.36 3.49 6.95 
N,N’-dmenPtCl2(OH)2 Calculated 12.38 3.64 7.22 
 Found 12.27 3.46 6.91 
enPtCl2OH(C4H5O4) Calculated 21.44 3.24 5.00 
 Found 21.25 2.97 5.11 
N,N-dmenPtCl2OH(C4H5O4) Calculated 19.68 3.72 5.74 
 Found 19.95 3.63 5.48 
enPtCl2(C6H9O4)2 Calculated 27.28 4.25 4.55 
 Found 26.63 4.09 4.35 
enPtCl2(C7H12O3N)2 Calculated 29.91 5.02 8.72 
 Found 30.00 4.86 8.30 
enPtCl2(C6H10O3N)2 Calculated 26.59 4.78 8.86 
 Found 26.47 4.64 8.61 
N,N-dmenPtCl2OH(C5H7O4) Calculated 21.52 4.01 5.58 
 Found 21.50 3.77 5.12 
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5.2.2 ESI-MS spectra 
ESI is a soft ionisation method and therefore allows non-destructive detection of 
molecules. These mass spectra show most of the mono-adducts that were formed with the 
matrix, like H+, Na+ or K+ adducts in positive ion mode or Cl- in negative. 
 
Table 3: Mass spectra data of selected compounds 
Compound M/[g/mol] [M+H+]+ [M+Na+]+ [M+K+]+ 
enPtCl2OH(C4H5O4) 560.3 561.5 582.8 598.7 
N,N-dmen-PtCl2OH(C4H5O4) 488.2 - 511.0 - 
enPtCl2(C7H12O3N)2 642.4 - 663.9 679.1 
enPtCl2(C6H9O4)2 616.4 - 637.9 654.8 
enPtCl2(C6H10O3N)2 614.4 - 637.1 - 
N,N-dmen-PtCl2OH(C5H7O4) 502.3 - 525.0 - 
N,N-dmen-PtCl2OH(C6H9O3N) 515.3 - 537.9 553.9 
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5.2.3 Infrared Spectroscopy 
IR spectroscopy is a useful method for quickly determining of a reaction’s success, 
especially the purity of compounds can be ascertained. The most important advantage of this 
method is the independency from the solubility of the compound, by reason that 
measurements are possible in all aggregate states. In particular for enPtCl2(OH)2  IR was the 
only method for structure-determination, beside elemental analysis, due to its insolubility. 
 
The complexation of ligands to a platinum centre has a remarkable effect on measured 
wavelengths. Depending on the distance to the platinum, ligands are shifted to lower 
wavelengths (reddish range) as observed for the C=O bond (general 1750-1735 cm-1, 
platinum bound 1650 cm-1) or the directly coordinated amines (general 3500-3300 cm-1, 
platinum bound 3200 cm-1) for example. 
 
Oxidation with Hydrogenperoxid 
The obtained hydroxido groups of the platinum(IV) compound after oxidation with hydrogen 
peroxide (see Figure 23) display one very characteristic peak at 3538 cm-1, that is attributable 
to the Pt-OH stretching vibration, the shape of which is very sharp and intense.  
 
 
 
Figure 23: IR-spectrum of N,N’-dmenPtCl2(OH)2 
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Acylation of the Dihydroxido Compounds 
IR spectroscopy is particularly useful for reaction control of the turnover of dihydroxido 
complexes with cyclic anhydrides. Here, the Pt-OH vibration disappears and the C=O peak 
between 1730-1600 cm-1 arises, if dicarboxylation takes place. 
The spectrum of the asymmetric product (see Figure 24) shows as expected both the Pt-
OH and the C=O signal. The broad absorption in the range of 3300-2700 cm-1 results from the 
amine, amide and saturated alkyl groups and is by reason of interferences not qualified for 
analysis. 
However, it can be determined whether the product is clean, as the substrate succinic 
anhydride has an absorption maximum typical at 1787 cm-1 from C=O vibration and the 
succinic acid at 1693 cm-1. 
Furthermore, the asymmetric vibrations of the C=O groups can be well differentiated. The 
peak at 1726 cm-1 can be referred to the uncoordinated carboxylic acid, whereas the shoulder 
at 1662 cm-1 is attributable to the coordinated one. 
 
 
 
Figure 24: IR-spectrum of N,N-dmenPtCl2OH(C4H5O4) 
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Derivatisation of the Free Carboxylic Acid 
Figure 25 shows the spectra of the two synthesised derivatives of enPtCl2(C4H5O4)2. Both the 
ester ((enPtCl2(C6H9O4) red graph) and the amide ((enPtCl2(C7H12O3N)2) blue graph) have an 
absorption maximum at about 3200 cm-1 that can be assigned to the N-H vibration. 
Differences can be illustrated through the varying C=O asymmetric stretches. These 
vibrations can be clearly differentiated by looking at the ester spectrum (ester: 1714 cm-1, 
platinum coordinated carboxylic acid: 1643 cm-1) while the two C=O peaks of the amide 
overlap at about 1738 cm-1 and only a small shoulder can be seen. 
 
 
 
Figure 25: IR-spectra of enPtCl2(C5H7O4)2 and enPtCl2OH(C6O3H10N)2 
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5.2.4 NMR Spectroscopy 
5.2.4.1 Asymmetric Platinum(IV) Complexes 
Since there are only a few asymmetric platinum(IV) compounds published, the focus will 
be put on the discussion of NMR data of N,N-dmenPtCl2OH(C4H5O4) (21) and its 
methylester. 
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Figure 26: Comparison of symmetric and asymmetric platinum(IV) compound 
 
 
In comparison to enPtCl2(C4H5O4)2 there is a break in symmetry. Consequently, the 
signal reduction that occurred in highly symmetric compounds is abrogated. The platinum 
centre functions as a chiral centre because of the presence of four different ligands. Therefore 
the amine protons (1 + 1’) and methyl groups (4 + 4’) became differentiable. 
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Figure 27: Comparison of 1H spectra of a symmetric and asymmetric platinum(IV) compound. 
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Interpretation of the 1H spectra without 2D-data is ambiguous; especially the adjacent 
methylene groups (C2/C3 and C6/C7) revealed very broad multipletts.  
Owing to the complexation of a platinum(IV) centre, platinum satellites of the methyl-
signals can be observed. The broadening of the multiplet shifted to lower field is attributable 
to the relaxation time of amines, and therefore can be associated with C2/C3. 
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Figure 28: Detail of HSQC spectrum of N,N-dmenPtCl2OH(C4H5O4) (21) 
 
By the use of HSQC and HMBC spectra the carbon signals could be assigned readily 
except for C6/C7. The differentiation of C2/C3 can be made considering the cross peaks of 
the carbon signal at 67.8 ppm (C3) to the methyl groups, whereas the signal at 45.2 ppm (C2) 
does not show these cross peaks. 
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Figure 29: Detail of HMBC spectrum of N,N-dmenPtCl2OH(C4H5O4) (21) 
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For assignment of the residual C6/C7 signals 
and the two quaternary carbons C5/C8, chemical 
correlation by comparison of the acid with the 
methyl ester derivative was used.  
 
Figure 30: N,N-dmenPtCl2OH(C5H7O4) 
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Figure 31: 1H spectrum of N,N-dmenPtCl2OH(C5H7O4) 
 
 
A closer look at the HMBC spectrum of N,N-dmenPtCl2OH(C5H7O4) shows a crosspeak 
of the shifted quarternary carbon signal (173.4 ppm) to H9 of the methyl ester, whereas the 
signal (C5) at 181.1 ppm did not.  
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Figure 32: Detail of HMBC spectrum of N,N-dmenPtCl2OH(C5H7O4) 
 
 
 
5.2.4.2 (SP-4-2)-Dichlorido(N,N’-dimethylethane-1,2-diamine)platinum(II) 
As mentioned before, N,N’-dmenPtCl2(OH)2 is a mixture of stereoisomers. The 
enantionmeres (A/B) can not be differentiated in NMR spectroscopy without a chiral 
environment, nevertheless the diastereomeres (A/C and B/C) induce different signals. At this 
point it has to be mentioned that compound C is not chiral, as it is a meso compound. 
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Figure 33: Stereoisomeric forms of N,N’-dmenPtCl2(OH)2 
 
The diastereomers show different signals in all measured spectra. The resultant peaks, for 
example at 195Pt spectrum, display different intensities. This fact permits a correlation of the 
signals to the isomer, after determination of the ratio. 
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Figure 34: 195Pt spectrum of N,N’-dmenPtCl2(OH)2 (20) 
 
In the 1H-NMR spectrum measured in D2O the acidic protons of the amino functions and 
the hydroxido groups can not be seen because of the rapid chemical exchange with D2O. Also 
in 1H and 13C spectra, there are two sets of signals for the diastereomeres, which can be 
related via HMBC-spectrum. 
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The methylene protons of the meso compound ((20) C) are split in two, nevertheless the 
methyl group show only one signal. It is obvious that the reason for this is attributable to a 
favoured conformation wit a mirror plane. 
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Figure 35: HMBC spectrum of N,N’-dmenPtCl2(OH)2 
 
 
 
 
After correlation of the isomers and the 
methyl groups, computation of the 
diastereomeres ratio was made. To afford 
analysis of the overlapping peaks, 
deconvolution was performed by using a 
Lorentzian function as an apodization function. 
The calculated relative integrations can be set 
in direct proportion to each other. 
A ratio of 1:1.4 of compound C to the 
enantiomeres A/B was determined. 
Figure 36: Deconvolution of the overlapping 
methyl groups of stereoisomeres. 
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6 Experimental Section 
6.1 General Remarks 
Platinum(II) compounds are prone to disproportion to metallic platinum and Platinum(IV) 
in presence of light, metals or metal compounds, accordingly all reactions were carried out 
with protection from light and with thrice distilled water, if necessary. Purification steps were 
also, if possible, performed with exclusion of light. Magnetic stirrers were coated with glass 
to prevent the possibility of reduction to platinum(II) with the ferromagnetic metal. 
All glassware needed for reactions was dried in compartment drier at 110°C. For 
reactions that are sensitive to atmospheric oxygen or moisture, they were operated under 
argon atmosphere and with use of anhydrous solvents. All magnetic stirrers and suction filters 
were cleaned by treatment with aqua regia to eliminate traces of platinum. 
The synthesised compounds were stored under argon atmosphere at 4°C. 
 
6.1.1 Chemicals 
All commercially available chemicals were purchased from Sigma Aldrich, Fluka, Acros 
or Merck and used without further purification, except for K2[PtCl4] from Johnson Matthey. 
Anhydrous DMF was bought by Sigma Aldrich and stored over molecular sieves (4 ). 
Methanol and ethanol were freshly distilled over CaO and Mg and CH2Cl2 over phosphorus 
pentoxide. Water was distilled thrice for removing traces of metal. 
 
For TLC Fluka silica gel TLC-PET foils (medium pore diameter 60 ) and for 
preparative column chromatography silica gel 60 also from Fluka (particle size 35-70 μm) 
were used. 
 
 
Experimental Section   53 
6.2 Instrumental Analysis 
Elemental Analysis 
The analyses were performed by the Microanalytical Laboratory of the University of 
Vienna, under the direction of Mag. Theiner. Determination of the composition (elements C, 
H and N) was performed on a 2400 CHN Elemental Analyser produced by Perkin Elmer. 
 
Infrared Spectroscopy 
IR-spectra were recorded on a Bruker Vertex 70 FT-IR-spectrometer with ATR-unit 
(attenuated total reflection unit) in the range of 4000-400 cm-1. 
 
Mass Spectrometry 
ESI-MS spectra were performed in methanol in positive and negative mode on a 
BRUKER Esquire3000 ion trap spectrometer. 
 
NMR Spectroscopy 
NMR spectra were recorded in d7-DMF, d6-DMSO and D2O, referring to the respective 
solubilities of the synthesised compounds, with a Bruker FT-NMR Avance III 500 MHz 
spectrometer at 500.32 (1H), 125.81 (13C), 107.55 (195Pt) MHz at 298 K. Chemical shifts 
(ppm) were referenced internal to the solvent residual peaks or external relative to K2[PtCl4]. 
For description of spin multiplicity the following abbreviations were used: s = singlet; 
d = duplet; m = multiplett; b = broad signal. 
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6.3 Platinum(II) Compounds 
6.3.1 (SP-4-2)-Dichlorido(ethane-1,2-diamine)platinum(II) 
 
K2[PtCl4] + NH2
NH2 Pt
Cl
Cl
N
H2
N
H2
MW = 415.0 g/mol
C2H8N2
MW = 60.0 g/mol
C2H8Cl2N2Pt
MW = 326.0 g/mol
 
 
Ethane-1,2-diamine (145 mg, 2.409 mmol) in tridest. H2O (6.5 mL) was added to a 
filtered solution of K2[PtCl4] (1 g, 2.409 mmol) in tridest. H2O (16.5 mL) and the mixture 
was stirred at rt. The precipitating product was repeatedly filtered off and washed with tridest. 
H2O. The filter crucible was changed when the colour of the precipitate was turning brown. 
The crude product was collected until the primarily red solution turned yellow and 
subsequently dried in vacuo. The impurified product could be recristallised from DMF to 
yield a yellow solid. 
 
Yield: 0.537 g = 1.648 mmol (68%) 
 
Analytical determination: 
Elemental analysis: C2H8Cl2N2Pt 
Element C H Cl N Pt 
Calculated 7.37 2.47 21.75 8.59 59.83 
Found 7.46 2.36 - 8.47 - 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3279, 3249, 3205, 3127 ν (N-H) 
2962, 2899 ν (C-H) 
1564 δ (N-H) 
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6.3.2 (SP-4-3)-Dichlorido(N,N-dimethylethane-1,2-diamine)platinum(II) 
 
K2[PtCl4] + NH2
N
Pt
Cl
Cl
N
N
H2
MW = 415.0 g/mol
C4H12N2
MW = 88.1 g/mol
C4H12Cl2N2Pt
MW = 354.1 g/mol
 
 
N,N-dimethylethane-1,2-diamine (212 mg, 2.409 mmol) in tridest. H2O (17 mL) was 
added to a filtered solution of K2[PtCl4] (1000 mg, 2.409 mmol) in tridest. H2O (6.5 mL), and 
the mixture was stirred at rt. The precipitating product was repeatedly filtered off and washed 
with tridest. H2O. The filter crucible was changed when the colour of the precipitate was 
turning brown. The yellow crystalline product was collected until the primarily red solution 
turned yellow and subsequently dried in vacuo. 
 
Yield: 0.497 g = 1.403 mmol (58%) 
 
Analytical determination: 
Elemental analysis: C4H12Cl2N2Pt 
Element C H Cl N Pt 
Calculated 13.57 3.42 20.02 7.91 55.09 
Found 13.40 3.05 - 7.92 - 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3211, 3126, 3019 ν (N-H) 
2989, 2926 ν (C-H) 
1569 δ (N-H) 
1452, 1391, 1307 δ (C-H) 
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6.3.3 (SP-4-2)/(SP-4-3)-Dichlorido(N,N’-dimethylethane-1,2-diamine)platinum(II) 
 
K2[PtCl4] +
NH
NH Pt
Cl
Cl
NH
NH
MW = 415.0 g/mol
C4H12N2
MW = 88.1 g/mol
C4H12Cl2N2Pt
MW = 354.1 g/mol
 
 
N,N’-dimethylethane-1,2-diamine (212 mg, 2.409 mmol) in tridest. H2O (17 mL) was 
added to a filtered solution of K2[PtCl4] (1000 mg, 2.409 mmol) in tridest. H2O (6.5 mL) and 
the mixture was stirred at rt. The precipitating product was repeatedly filtered off and washed 
with tridest. H2O. The filter crucible was changed when the colour of the precipitate was 
turning brown. The light yellow product was collected until the primarily red solution turned 
yellow and dried in vacuo. 
 
Yield: 0.487 g = 1.375 mmol (57%) 
 
Analytical determination: 
Elemental analysis: C4H12Cl2N2Pt 
Element C H Cl N Pt 
Calculated 13.57 3.42 20.02 7.91 55.09 
Found 13.61 3.18 - 7.84 - 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3123 ν (N-H) 
2936, 2854 ν (C-H) 
1732, 1633, 1617 δ (N-H) 
1455, 1428 δ (C-H) 
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6.4 Oxidation to Platinum(IV) 
6.4.1 (OC-6-33)-Dichlorido(ethane-1,2-diamine)dihydroxidoplatinum(IV) 
 
Pt
ClN
H2+
N
H2
+
Cl
OH
OH
Pt
Cl
Cl
N
H2
N
H2
C2H8Cl2N2Pt
MW = 326.0 g/mol
C2H10Cl2N2O2Pt
MW = 360.1 g/mol
 
 
enPtCl2 (537 mg, 1.648 mmol) was suspended in tridest. H2O (14 mL) and 30% H2O2 
(14 mL) was added. After stirring at rt for 30 min the mixture was refluxed for 10 min. The 
suspension was cooled down to rt and was left in the refrigerator overnight. The pale yellow 
precipitate was filtered off, washed with tridest. H2O, ethanol and diethylether and dried in 
vacuo. 
 
Yield: 0.406 g = 1.127 mmol (68%) 
 
Analytical determination: 
Elemental analysis: C2H10Cl2N2O2Pt 
Element C H Cl N O Pt 
Calculated 6.67 2.80 19.69 7.78 8.89 54.17 
Found 6.41 2.51 - 7.42 - - 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3480 ν (Pt-OH) 
3157 ν (N-H) 
2951-2904 ν (C-H) 
1586 δ (N-H) 
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6.4.2 (OC-6-43)-Dichlorido(N,N-dimethylethane-1,2-diamine)dihydroxidoplatinum(IV) 
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N,N-dmenPtCl2 (900 mg, 2.541 mmol) was suspended in tridest. H2O (22 mL) and 30% 
H2O2 (22 mL) was added. After stirring at rt for about 1 h the suspension turned clear. The 
yellow solution was filtered and the solvent was removed under reduced pressure to gain a 
yellow solid. The residue was repeatedly dissolved in tridest. H2O and carefully concentrated 
to remove peroxides completely (caution: peroxide). The obtained product was dried in 
vacuo. 
 
Yield: 0.980 g = 2.525 mmol (99%) 
 
Analytical determination: 
Elemental analysis: C4H14Cl2N2O2Pt 
Element C H Cl N O Pt 
Calculated 12.38 3.64 18.27 7.22 8.24 50.26 
Found 12.36 3.49 - 6.95 - - 
 
1H-NMR (D2O): δ = 2.67 (t, 6H, H2); 2.89 (m, 4H, H1) ppm 
 
Experimental Section   59 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3596 ν (Pt-OH) 
3248, 3212 ν (N-H) 
2915 ν (C-H) 
1594 δ (N-H) 
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6.4.3 (OC-6-33)/(OC-6-43)-Dichlorido(N,N’-dimethylethane-1,2-diamine)dihydroxido 
platinum(IV) 
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N,N’-dmenPtCl2 (2 g, 5.648 mmol) was suspended in tridest. H2O (50 mL) and 30 % 
H2O2 (50 mL) was added. After stirring at rt for about 2.5 h the suspension turned clear. The 
yellow solution was filtered and the solvent was removed under reduced pressure to gain a 
yellow solid. The residue was repeatedly dissolved in tridest. H2O and concentrated to remove 
peroxides completely (caution: peroxide). The obtained mixture of isomeres was dried in 
vacuo. 
 
Yield: 2.19 g = 5.643 mmol (100%) 
 
Analytical determination: 
Elemental analysis: C4H14Cl2N2O2Pt 
Element C H Cl N O Pt 
Calculated 12.38 3.64 18.27 7.22 8.24 50.26 
Found 12.27 3.46 - 6.91 - - 
 
1H-NMR (D2O): δ = 2.49 (s+d, H2’); 2.54 (s+d, H2); 2.78 (m, H1’), 3.05 (m, 
H1-H1’) ppm 
 
13C-NMR (D2O): δ = 37.9 (C2’) ; 38.8 (C2); 55.9 (C1’); 56.2 (C1) ppm 
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195Pt NMR (D2O): δ = 2335; 2346 ppm 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3538 ν (Pt-OH) 
3016, 2986, 2941 ν (N-H) 
2789 ν (C-H) 
1633 δ (N-H) 
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6.5 Carboxylation with Succinic Anhydride 
6.5.1 (OC-6-33)-Bis(3-carboxypropanoato)dichlorido(ethane-1,2-diamine) 
platinum(IV) 
 
O
O
O
C4H4O3
MW = 100.1 g/mol
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enPtCl2(OH)2 (400 mg, 1.111 mmol) and succinic anhydride (456 mg, 4.555 mmol) were 
suspended in DMF (8 mL). The suspension was stirred at 70 °C until the solution turned clear. 
The solvent was removed under reduced pressure and the brown residue was dissolved in 
acetone. The mixture was filtered, concentrated under reduced pressure and the pale yellow 
solid was precipitated by slow addition of diethyl ether. 
 
Yield: 490 mg = 0.875 mmol (79%) 
 
Analytical determination: 
Elemental analysis: C10H8Cl2N2O8Pt 
Element C H Cl N O Pt 
Calculated 21.44 3.24 12.66 5.00 22.85 34.82 
Found 21.25 2.97 - 5.11 - - 
 
1H-NMR (d6-DMSO): δ = 2.39 (t, 4H, H3 or H4, 3JH-H = 7.0 Hz); 2.50 (t, 4H, H3 or H4, 
3JH-H = 6.7 Hz); 2.65 (bs, 4H, H1); 8.46 (bs, 4H, H2); 12.08 (bs, 2H, H5) ppm 
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IR (4000 – 400 cm-1) selected bands in cm-1: 
3465 ν (-COOH) 
3198 ν (N-H) 
3040-2929 ν (C-H) 
1711, 1652 νas (C=O) 
1592 δ (N-H) 
 
ESI-MS: Mr = 560.3 g/mol 
MS+ in MeOH: 
[m/z]+ molecular formula Ion 
 1140.9 C20H36Cl4N4O16Pt2Na [2M+Na]+ 
 598.7 C10H18Cl2N2O8PtK [M+K]+ 
 582.8 C10H18Cl2N2O8PtNa [M+Na]+ 
 561.5 C10H19Cl2N2O8Pt [M+H]+ 
 347.0 C2H8Cl2N2Pt [M+Na]+ - axial ligands 
 
MS- in MeOH 
[m/z]+ molecular formula Ion 
 1117.7 C20H37Cl4N4O16Pt2 [2M-H]- 
 558.9 C10H17Cl2N2O8Pt [M-H]- 
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6.5.2 (OC-6-54)-(3-Carboxypropanoato)dichlorido(N,N-dimethylethane-1,2-diamine) 
hydroxideplatinum(IV) 
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N,N-dmenPtCl2(OH)2 (800 mg, 2.061 mmol) and succinic anhydride (845 mg, 
8.450 mmol) were suspended in DMF (16 mL). The suspension was stirred at 70 °C for 18h, 
after about 30 min the solution turned clear. The solvent was removed under reduced pressure 
and the yellow residue was dissolved in acetone. The mixture was filtered, concentrated under 
reduced pressure and the pale yellow solid was precipitated by slow addition of diethyl ether. 
 
Yield: 738 mg = 1.511 mmol (73%) 
 
Analytical determination: 
Elemental analysis: C8H18Cl2N2O5Pt 
Element C H Cl N O Pt 
Calculated 19.68 3.72 14.52 5.74 16.39 39.96 
Found 19.95 3.63 - 5.48 - - 
 
1H-NMR (d6-DMSO): δ = 2.41 (m, 4H, H6/H7); 2.60 (bs, 3H, H4 or H4’); 2.68 (bs, 3H, 
H4 or H4’); 2.81 (m, 4H, H2/H3); 7.12 (bs, 1H, H1); 9.39 (bs, 1H, H1); 12.09 (bs, 2H, 
H9) ppm 
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13C-NMR (d6-DMSO): δ = 30.4 (C6 or C7); 32.5 (C6 or C7); 45.2 (C2); 48.6 (C4 or C4’); 
50.1 (C4 or C4’); 67.8 (C3); 174.6 (C10); 181.3 (C7) ppm 
 
195Pt NMR (d6-DMSO): δ = 2497 ppm 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3477 ν (Pt-OH) 
3081 ν (N-H) 
2936 ν (C-H) 
1726 νas (C=O) 
1598 δ (N-H) 
 
ESI-MS: Mr = 488.2 g/mol 
MS+ in MeOH: 
[m/z]+ molecular formula ion 
 511.0 C8H18Cl2N2O5PtNa [M+Na]+ 
 493.1 C8H16Cl2N2O4PtNa [M+Na]+ - H2O 
 375.2 C4H12Cl2N2Pt [M+Na]+ - 2*axial ligands 
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6.5.3 (OC-6-33)/(OC-6-43)-Bis(3-carboxypropanoato)dichlorido(N,N’-dimethylethane-
1,2-diamine)platinum(IV) 
 
O
O
O
C4H4O3
MW = 100.1 g/mol
DMF, 70°C
+Pt
ClNH
+
NH
+
Cl
OH
OH
C4H14Cl2N2O2Pt
MW = 388.1 g/mol
Pt
ClNH
+
NH
+
Cl
O
O
OH
O
O
OH
O
O
C12H22Cl2N2O8Pt
MW = 588.3 g/mol
Pt
ClNH
+
NH
+
Cl
O
OH
OH
O
O
+
C8H18Cl2N2O5Pt
MW = 488.2 g/mol
 
 
N,N’dmen-PtCl2(OH)2 (1.60 g, 4.123 mmol) and succinic anhydride (1.69 mg, 
16.492 mmol) were suspended in DMF (32 mL). The yellow suspension was stirred at 70 °C 
for 18 h, after about 1 h the solution turned clear and the colour turned to reddish brown. The 
solvent was removed under reduced pressure and the brown residue was dissolved in acetone. 
The mixture was filtered, concentrated under reduced pressure and the brown solid was 
precipitated by slow addition of diethyl ether. A mixture of mono- and dicarboxylated product 
was obtained. 
 
Analytical determination: 
Elemental analysis: C12H22Cl2N2O8Pt 
Element C H Cl N O Pt 
Dicarboxylated 24.50 3.77 12.05 4.76 21.76 33.16 
monocarboxylyted 19.68 3.72 14.52 5.74 16.39 39.96 
Found 20.21 3.39 - 5.51 - - 
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IR (4000 – 400 cm-1) selected bands in cm-1: 
3454 ν (-COOH) 
3127 ν (N-H) 
2941-2872 ν (C-H) 
1721, 1621 νas (C=O) 
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6.6 Derivatisation of the Carboxyl Group 
6.6.1 (OC-6-33)-Dichlorido(ethane-1,2-diamine)-bis[4-(propylamino)-4-
oxobutanoato]platinum(IV) 
 
C10H18Cl2N2O8Pt
MW = 560.3 g/mol
Pt
ClN
H2+
N
H2
+
Cl
O
O
OH
O
O
OH
O
O
Pt
ClN
H2+
N
H2
+
Cl
O
O
NH
O
O
NH
O
O
C16H32Cl2N4O6Pt
MW = 642.4 g/mol
1. CDI, Δ
2. propylamine
1
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4
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enPtCl2(C4H5O4)2 (200 mg, 0.357 mmol) was dissolved in 4 mL DMF under argon 
atmosphere. The yellow solution was heated to 70 °C and 1,1-carbonyldiimidazole (118.6 mg, 
0.732 mmol) in 8 mL DMF was added. After stirring for 10 min the solution was allowed to 
cool to rt when simultaneously flushing with argon to remove emerging CO2. Then 
propylamine (60.4 μL, 0.732 mmol) in 12 mL DMF was added, after stirring for 24 h the 
solvent was removed under reduced pressure to get a brown oil. The residue was dissolved in 
MeOH and purified by column chromatography (silica, MeOH:EE = 1:4). 
 
Yield: 0.143 g = 0.223 mmol (62%) 
 
Analytical determination: 
Elemental analysis: C16H32Cl2N4O6Pt 
Element C H Cl N O Pt 
Calculated 29.91 5.02 11.04 8.72 14.94 30.37 
Found 30.00 4.86 - 8.30 - - 
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1H-NMR (d6-DMSO): δ = 0.83 (t, 6H, H8, 3JH, H = 7.4 Hz); 1.38 (m, 4H, H7); 2.28 (t, 4H, 
H3 or H4, 3JH, H = 7.3 Hz); 2.46 (t, 4H, H3 or H4, 3JH, H = 7.3 Hz); 2.67 (bs, 4H, H1); 2.98 (m, 
4H, H6); 7.77 (t, 2H, H5, 3JH, H = 5.5 Hz); 8.44 (bs, 4H, H2) ppm 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3294, 3202 ν (N-H) 
3040-2929 ν (C-H) 
1711, 1652 νas (C=O) 
1551 δ (N-H) 
 
ESI-MS: Mr = 642.4 g/mol 
MS+ in MeOH: 
[m/z]+ molecular formula ion 
 679.1 C16H32Cl2N4O6PtK [M+K]+ 
 663.9 C16H32Cl2N4O6PtNa [M+Na]+ 
 505.8 C9H20Cl2N3O3PtNa [M+Na]+ - 1*axial ligand 
 346.9 C2H8Cl2N2Pt [M+Na]+ - 2*axial ligands 
 
MS- in MeOH 
[m/z]+ molecular formula ion 
 641.3 C16H33Cl2N4O6Pt [M+H]- 
 676.8 C16H32Cl2N4O6PtCl [M+Cl]- 
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6.6.2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)bis[(4-ethoxy)-4-oxo-
butanoato]platinum(IV) 
 
C10H18Cl2N2O8Pt
MW = 560.3 g/mol
Pt
ClN
H2+
N
H2
+
Cl
O
O
OH
O
O
OH
O
O
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H2+
N
H2
+
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O
O
O
O
O
O
O
O
1. CDI, Δ
2. NaOEt
C14H26Cl2N2O8Pt
MW = 616.4 g/mol
1
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4
2
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enPtCl2(C4H5O4)2 (200 mg; 0.357 mmol) was dissolved in 4 mL DMF under an argon 
atmosphere. The yellow solution was heated to 70 °C and 1,1-carbonyldiimidazole (118.6 mg, 
0.732 mmol) in 8 mL DMF was added. After stirring for 10 min the solution was allowed to 
cool to rt when simultaneously flushing with argon to remove emerging CO2. Dissolving 
sodium (about 6 mg) in anhydrous EtOH (10 mL) gave a mixture of ethanolate/ethanol which 
was added to the reaction mixture. The reaction mixture was stirred for 24 h and subsequently 
the solvent was removed under reduced pressure to get a brown oil. The residue was dissolved 
in MeOH and purified by column chromatography (silica, MeOH:EE = 1:7). 
 
Yield: 0.052 g = 0.084 mmol (24%) 
 
Analytical determination: 
Elemental analysis: C14H26Cl2N2O8Pt 
Element C H Cl N O Pt 
Calculated 27.28 4.25 11.50 4.55 20.77 31.65 
Found 26.63 4.09 - 4.35 - - 
 
1H-NMR (d6-DMSO): δ = 1.19 (m, 6H, H6); 2.46 (t, 4H, H3 or H4, 3JH, H = 6.3 Hz); 2.54 
(t, 4H, H3 or H4, 3JH, H = 6.4 Hz); 2.65 (bs, 4H, H1); 4.06 (m, 4H, H5); 8.43 (bs, 4H, H2) ppm 
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IR (4000 – 400 cm-1) selected bands in cm-1: 
3196 ν (N-H) 
2984-2929 ν (C-H) 
1714, 1643 νas (C=O) 
1543 δ (N-H) 
 
ESI-MS: Mr = 616.4 g/mol 
MS+ in MeOH: 
[m/z]+ Molecular formula ion 
 637.9 C14H26Cl2N2O8PtK [M+K]+ 
 654.8 C14H26Cl2N2O8PtNa [M+Na]+ 
 492.8 C8H17Cl2N2O4PtNa [M+Na]+ - 1*axial ligand 
 346.9 C2H8Cl2N2Pt [M+Na]+ - 2*axial ligands 
 
MS- in MeOH 
[m/z]+ Molecular formula ion 
 641.3 C14H27Cl2N2O8Pt [M+H]- 
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6.6.3 (OC-6-33)-Dichlorido(ethan-1,2-diamine)bis[(4-dimethylamine)-4-oxobutanoato] 
platinum(IV) 
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O
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MW = 281.1 g/mol
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N,N-dmenPtCl2(C4H5O4)2 (300 mg, 0.535 mmol) and 1-(dimethylcarbamoyl)-3-methyl-
1H-imidazol-3-ium iodide (309 mg, 1.098 mmol) were dissolved in 2 mL DMF under argon 
atmosphere and triethylamine (111 mg, 1.098 mmol) was added. The suspension was heated 
to 60 °C and after 1 h a clear, reddish brown solution was obtained. The reaction mixture was 
stirred for 24 h and subsequently the solvent was removed under reduced pressure to get a 
brown oil. The residue was dissolved in MeOH and purified by column chromatography 
(silica, MeOH:EE = 1:1). 
 
Yield: 0.125 g = 0.203 mmol (38%) 
 
Analytical determination: 
Elemental analysis: C14H28N4Cl2O6Pt*1H2O 
Element C H Cl N O Pt 
Calculated 26.59 4.78 11.21 8.86 17.71 30.85 
Found 26.47 4.64 - 8.61 - - 
 
1H-NMR (d6-DMSO): δ = 2.47 (bs, 8H, H4-H5); 2.69 (bs, 4H, H1); 2.80 (s, 6H, H7 or 
H7’); 2.96 (s, 6H, H7 or H7’); 8.45 (bs, 4H, H2) ppm 
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13C-NMR (d6-DMSO): δ = 28.9 (C5); 31.7 (C4); 35.4 (C7 or C7’); 37.0 (C7 or C7’); 
49.0 (C1); 171.6 (C6); 182 (C3) ppm 
 
195Pt-NMR (d6-DMSO): δ = 2659 ppm 
 
ESI-MS: Mr = 614.4 g/mol 
MS+ in MeOH: 
[m/z]+ Molecular formula ion 
 637.1 C14H28N4Cl2O6PtNa [M+Na]+ 
 491.0 C8H18N3O3Cl2PtNa [M+Na]+ - 1*axial ligand 
 347.0 C2H8N2Cl2PtNa [M+Na]+ - 2*axial ligands 
 
MS- in MeOH 
[m/z]+ Molecular formula ion 
 613.0 C14H27N4Cl2O6Pt [M+H]- 
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6.6.4 (OC-6-54)-Dichlorido(N,N-dimethylethane-1,2-diamine)hydroxido[(4-methoxy)-
4-oxo-butanoato]platinum(IV) 
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N,N-dmenPtCl2OH(C4H5O4) (200 mg, 0.409 mmol) was dissolved in 4 mL DMF under 
argon atmosphere. The yellow solution was heated to 70 °C and CDI (136 mg, 0.839 mmol) 
in 8 mL DMF was added. After stirring for 10 min the solution was allowed to cool to rt when 
simultaneously flushing with argon to remove emerging CO2. Dissolving sodium (about 
6 mg) in anhydrous MeOH gave a mixture of methanolate/methanol which was added to the 
reaction mixture. The reaction mixture was stirred at rt for 24 h and subsequently the solvent 
was removed under reduced pressure to get a brown oil. The residue was resolved in MeOH 
and purified by column chromatography (silica, MeOH:EE = 1:1). 
 
Yield: 0.045 g = 0.089 mmol (22%) 
 
Analytical determination: 
Elemental analysis: C9H20Cl2N2O5Pt 
Element C H Cl N O Pt 
Calculated 21.52 4.01 14.12 5.58 15.93 38.84 
Found 21.50 3.77 - 5.12 - - 
 
1H-NMR (d7-DMF): δ = 1.59 (bs, 1H, H10); 2.56 (m, 4H, H6/H7); 2.77 (t, 3H, H4 or 
H4’); 2.84 (t, 3H, H4 or H4’); 3.06 (m, 4H, H2/H3); 3.64 (s, 3H, H9); 7.25 (bs, 1H, H1); 9.73 
(bs, 2H, H1) ppm 
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13C-NMR (d7-DMF): δ = 29.8 (C6 or C7); 32.2 (C6 or C7); 45.1 (C2); 48.1 (C4 or C4’); 
49.7 (C4 or C4’); 51.1 (C9); 67.8 (C3); 173.4 (C8); 181.1 (C5) ppm 
 
195Pt-NMR (d7-DMF): δ = 2457 ppm 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3480 ν (Pt-OH) 
2923-2852 ν (C-H) 
1723, 1626 νas (C=O) 
1559 δ (N-H) 
 
ESI-MS: Mr = 502.3 g/mol 
MS+ in MeOH: 
[m/z]+ molecular formula ion 
 525.0 C9H20Cl2N2O5PtNa [M+Na]+ 
 375.2 C4H12Cl2N2PtNa [M+Na]+ - axial ligands 
 339.3 C4H11ClN2PtNa [M+Na]+ - axial ligands + HCl 
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6.7 Click Chemistry 
6.7.1 (OC-6-33)-Bis{4-{[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amino}-4-oxo-
butanoato}dichlorido(ethane-1,2-diamine)platinum(IV) 
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enPtCl2(C7H8O3N)2 (100 mg, 0.158 mmol) and benzylazide (41.9 mg, 0.315 mmol) were 
suspended in 3 mL of tridest. H2O and a catalytic amount of CuBr (2 mg, 0.016 mmol) and 
Me2S (5.9 mg, 0.095 mmol) were added. The reaction mixture was stirred at rt for 24 h. The 
solid was filtered off and washed with water, ethanole and diethylether to yield a green 
product. Due to the bad solubility further purification was impossible. 
 
Analytical determination: 
1H-NMR (d6-DMSO): δ = 2.50 (m, 8H, H3/H4); 2.64 (bs, 4H, H1); 4.27 (bs, 4H, H6); 
5.56 (s, 4H, H8); 7.36 (m, 10H, H9-H11); 7.99 (s, 2H, H7); 8.31 (bs, 2H, H5); 8.42 (bs, 4H, 
H2) ppm 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3293,56 ν (N-H) 
2988-2928 ν (C-H) 
1641 νas (C=O) 
1564 δ (N-H) 
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6.7.2 (OC-6-33)-Bis{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]-4-oxo-
butanoato}dichlorido(ethane-1,2-diamine)platinum(IV) 
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enPtCl2(C2H5O4)2 (100 mg, 0.178 mmol) was dissolved in 1.5 mL DMF under argon 
atmosphere. The yellow solution was heated to 70 °C and CDI (59 mg, 0.366 mmol) in 3 mL 
DMF was added. After stirring for 10 min, the solution was allowed to cool to rt when 
simultaneously flushing with argon to remove emerging CO2. Dissolving sodium (about 
6 mg) in a solution of (1-benzyl-1H-1,2,3-triazole-4-yl)methanol (100 mg, 0.529 mmol) in 
3 mL anhydrous THF gave the corresponding alkoxide. THF was removed under reduced 
pressure and to the exclusion of air and water and the alkoxide was resolved in 3 mL DMF. 
This solution was added to the reaction mixture. After stirring for 24 h the solvent was 
removed under reduced pressure to get a yellow oil. The residue was dissolved in MeOH and 
a brown residue was obtained. The residue was filtered off and washed with water, methanol 
and diethylether. Due to the bad solubility further purification was impossible. 
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Analytical determination: 
1H-NMR (d6-DMSO): δ = 2.52 (m, 8H, H3/H4); 2.62 (bs, 4H, H1); 5.12 (s, 4H, H5); 5.60 
(s, 4H, H7); 7.36 (m, 10H, H8-H10); 8.19 (s, 2H, H6); 8.40 (bs, 4H, H2) ppm 
 
IR (4000 – 400 cm-1) selected bands in cm-1: 
3196 ν (N-H) 
2980-2850 ν (C-H) 
1730, 1643 νas (C=O) 
 
ESI-MS: Mr = 902.6 g/mol 
MS+ in MeOH: 
[m/z]+ Molecular formula ion 
 942.1 C30H36Cl2N8O8PtK [M+K]+ 
 925.6 C30H36Cl2N8O8PtNa [M+Na]+ 
 888.2 C30H35ClN8O8PtNa [M+Na]+-HCl 
 636.0 C16H22Cl2N5O4PtNa [M+Na]+ - 1*ligand 
 346.9 C2H8Cl2PtNa [M+Na]+ - 2*ligand 
 312.1 C14O4N3H15Na [ligand+Na]+ 
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6.8 Synthesis of Ligands 
6.8.1 Benzylazid 
 
Cl
H2O, EtOH, NaN3
N3
C7H7Cl
MW = 126.58
C7H7N3
MW = 133.15
1
2
3
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Benzylchloride (6.0 g; 47.5 mmol) and sodiumazide (3.4 g, 52.2 mmol) were dissolved in 
EtOH/H2O (48 mL, 7:1). The reaction mixture was refluxed for 24 h. The solution was slowly 
cooled to rt and then poured on H2O (220 mL). The aqueous layer was extracted with 
diethylether (3x80 mL). The combined organic layer was washed with water, dried with 
Na2SO4, filtered and concentrated in vacuo to yield a clear solution. 
 
Yield = 4.98 g = 0.037 mol (78 %) 
 
Analytical determination: 
1H-NMR (d6-DMSO): δ = 4.46 (s, 2H, H1); 7.39 (m, 5H, H2-H4) ppm 
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6.8.2 (1-Benzyl-1H-1,2,3-triazole-4-yl)methanol 
 
OH + N3
OH
N
N
N
C3H4O
MW = 56.06
C7H7N3
MW = 133.15
C10H11N3O
MW = 189.21
CuSO4
Sodium Ascorbate 1
3
4
2
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Benzylazide (1.00 g; 7.51 mmol) and propargylalcohol (0.42 g, 7.51 mmol) were 
dissolved in THF (40 mL). CuSO4*5H2O (94 mg, 0.375 mmol) and sodium ascorbate 
(297 mg, 1.49 mmol) in H2O (25 mL) were added. The yellow suspension was stirred for 7 h 
at rt. The solvent was removed under reduced pressure and the residue was redissolved in 
toluene. The organic layer was washed with H2O and brine, dried with MgSO4 and 
concentrated under reduced pressure to yield a white solid. The product was recrystallized in 
toluene to receive white needles. 
 
Yield: 0.705 g = 3.73 mmol (50 %) 
 
Analytical determination: 
Elemental analysis: C10H11N3O 
Element C H Cl N O Pt 
Calculated 63.48 5.86 - 22.21 8.46 - 
Found 63.55 5.69 - 22.09 - - 
 
1H-NMR (d6-DMSO): δ = 4.51 (d, 2H, H2, 3JH, H = 5.7 Hz); 5.15 (t, 1H, H1, 3JH, H = 5.7 
Hz); 5.57 (s, 2H, H4); 7.35 (m, 5H, H5-H7); 8.01 (s, 1H, H3) ppm 
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6.8.3 N,N-Dimethyl-1H-imidazole-1-carboxamide 
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1,1-carbonyldiimidazol (1.40 g, 8.637 mmol) and triethylamine (850 mg, 8.400 mmol) 
were dissolved in 20 mL of absolute CH2Cl2. The solution was cooled to 0 °C and 
dimethylamine hydrochloride (500 mg, 6.135 mmol) was slowly added. After about 10 min 
the solution was allowed to reach rt and was stirred over night. Then the reaction mixture was 
quenched with water, the aqueous layer was extracted thrice with CH2Cl2. The organic layers 
were combined, dried with Na2SO4, filtrated and the solvent was removed under reduce 
pressure to yield white crystals. 
 
Yield: 782 mg = 5.622 mmol (92%) 
 
Analytical determination: 
1H-NMR (d6-DMSO): δ = 3.01 (bs, 6H, H1); 7.02 (m, 1H, H4) 7.50 (t, 1H, H3, 3JH, H = 1.4 
Hz); 8.05 (t, 1H, H2, 3JH, H = 0.9 Hz) ppm 
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6.8.4 1-(Dimethylcarbamoyl)-3-methyl-1H-imidazol-3-ium iodide 
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N,N-dimethyl-1H-imidazole-1-carboxamide (750 mg, 5.392 mmol) was dissolved in 
10 ml of acetonitril p.a. and methyliodid (3.06 g, 21.56 mmol) was added slowly. The 
reaction mixture was stirred over night and meanwhile the clear colourless solution turned 
yellow. The solvent was removed under reduced pressure to yield a yellow oil. 
 
Yield: 1.17 g = 4.163 mmol (77%) 
 
Analytical determination: 
1H-NMR (d6-DMSO): δ = 3.06 (bs, 6H, H1); 3.92 (s, 3H, H5); 7.84 (t, 1H, H2, 3JH, H = 2.0 
Hz); 8.06 (t, 1H, H3, 3JH, H = 1.8 Hz); 9.58 (s, 1H, H4) ppm 
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List of Abbreviations 
 
gDNA genomic deoxyribonucleic acid 
RNA ribonucleic acid 
A adenine 
G guanine 
 
DMF dimethyl formamide 
DMSO dimethyl sulfoxide 
CDI 1,1-carbonyldiimidazole 
HPLC high performance liquid chromatography 
TLC thin layer chromatography 
ESI MS electrospray ionisation mass spectrometry 
 
Arg (R) arginine 
Gly (G) glycine 
Asp (D) aspartic acid 
Asn (N) asparagine 
Ala (A) alanine 
 
h hour 
min minute 
rt room temperature 
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Shortcuts for Platinum(IV) Complexes 
 
enPtCl2 (SP-4-2)-Dichlorido(ethane-1,2-diamine)platinum(II) 
 
N,N-dmenPtCl2 (SP-4-3)-Dichlorido(N,N-dimethylethane-1,2-diamine) 
 platinum(II) 
 
N,N’-dmenPtCl2 (SP-4-2)/(SP-4-3)-Dichlorido(N,N’-dimethylethane-1,2- 
 diamine)platinum(II) 
 
enPtCl2(OH)2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)dihydroxido 
 platinum(IV) 
 
N,N-dmenPtCl2(OH)2 (OC-6-43)-Dichlorido(N,N-dimethylethane-1,2-diamine) 
 dihydroxidoplatinum(IV) 
 
N,N’-dmenPtCl2(OH)2 (OC-6-33)/(OC-6-43)-Dichlorido(N,N’-dimethylethane-1,2- 
 diamine)dihydroxidoplatinum(IV) 
 
enPtCl2(C4H5O4)2 (OC-6-33)-Bis(3-carboxypropanoato)dichlorido(ethane-1,2- 
 diamine)platinum(IV) 
 
N,N-dmenPtCl2OH(C4H5O4) (OC-6-54)-(3-Carboxypropanoato)dichlorido(N,N-dimethyl 
 ethane-1,2-diamine)hydroxidoplatinum(IV) 
 
N,N’-dmenPtCl2(C4H5O4)2 (OC-6-33)/(OC-6-43)-Bis(3-Carboxypropanoato)dichlorido  
 (N,N’-dimethylethane-1,2-diamine)platinum(IV) 
 
enPtCl2(C7H8O3N)2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)bis(4-oxo-4- 
 (ethenylamino)butanoato)platinum(IV) 
 
enPtCl2(C7H12O3N)2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)bis[4-(propyl  
 amino)-4-oxobutanoato]platinum(IV) 
 
enPtCl2(C6H9O4)2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)bis[(4-ethoxy)-4- 
 oxobutanoato]platinum(IV) 
 
enPtCl2(C6H10O3N)2 (OC-6-33)-Dichlorido(ethane-1,2-diamine)bis[(4-dimethyl  
 amine)-4-oxobutanoato]platinum(IV) 
 
N,N-dmenPtCl2OH(C5H7O4) (OC-6-54)-Dichlorido(N,N-dimethylethane-1,2-diamine) 
 [(4-methoxy)-4-oxobutanoato)]hydroxidoplatinum(IV) 
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